SI-BONE, Inc. (SIBN)
NASDAQ: SIBN · Real-Time Price · USD
12.36
-0.79 (-6.01%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.

It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.

The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.

The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers.

SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SI-BONE, Inc.
SI-BONE logo
Country United States
Founded 2008
IPO Date Oct 17, 2018
Industry Medical Devices
Sector Healthcare
Employees 376
CEO Laura Francis

Contact Details

Address:
471 El Camino Real, Suite 101
Santa Clara, California 95050
United States
Phone 408 207 0700
Website si-bone.com

Stock Details

Ticker Symbol SIBN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001459839
CUSIP Number 825704109
ISIN Number US8257041090
Employer ID 26-2216351
SIC Code 3841

Key Executives

Name Position
Laura A. Francis MBA Chief Executive Officer and Director
Jeffrey W. Dunn Executive Chairman
Anshul Maheshwari Chief Operating Officer and Chief Financial Officer
Anthony J. Recupero Advisor
Dr. Scott A. Yerby Ph.D. Senior Vice President of Engineering and Chief Technology Officer
Saqib Iqbal Vice President of Financial Planning and Analysis and Investor Relations
Michael A. Pisetsky J.D. Chief Business and Legal Affairs Officer, Secretary and General Counsel
Ian Bailey Vice President of Product and Marketing
Dr. Daniel Joseph Cher M.D. Senior Vice President of Clinical, Regulatory Affairs and Quality
Dr. W. Carlton Reckling M.D. Chief Medical Officer and Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Apr 24, 2026 SCHEDULE 13G/A Filing
Apr 21, 2026 ARS Filing
Apr 21, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2026 DEF 14A Other definitive proxy statements
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 12, 2026 144 Filing
Feb 24, 2026 S-8 Securities to be offered to employees in employee benefit plans
Feb 24, 2026 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 24, 2026 10-K Annual Report
Feb 23, 2026 8-K Current Report